Guodong Man
Papers
2
Total Citations
9
H-Index
2
About
Guodong Man is a surgical oncologist and clinical researcher whose work centers on the treatment of head and neck cancers, with a particular focus on human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). His major contributions lie in pioneering de-escalation strategies that combine neoadjuvant immunochemotherapy with minimally invasive transoral robotic surgery (TORS). In a landmark single-arm, phase 2 trial, Man demonstrated that the anti-PD-1 agent sintilimab, given with platinum-doublet chemotherapy before TORS, yields high major pathological response rates in HPV-positive resectable OPC—a finding that challenges traditional chemoradiation paradigms and offers a pathway to reduce treatment toxicity. This work, published in 2024 and 2025, has already garnered nearly 10 citations, signaling its rapid impact on the field. By integrating immunotherapy into the surgical window, Man is helping to reshape the standard of care for a growing population of younger, HPV-driven cancer patients, balancing oncologic efficacy with functional preservation. His research is a compelling example of how precision medicine and surgical innovation can converge to improve outcomes.
Research Focus
Key Achievements
Top Papers
- 1
- 2